Connie Lee Batlevi, MD

Connie Batlevi, MD, PhD, detailed important updates in therapies for relapsed/refractory follicular lymphoma in this episode of CancerNetwork’s® podcast.

Connie Batlevi, MD, PhD, discusses how the sequencing of follicular lymphoma therapies has changed in the past year and looks to the future with the upcoming American Society of Hematology (ASH) annual meeting.

Connie Batlevi, MD, PhD, explains the recent approval of tazemetostat, as well as the use of molecular testing in follicular lymphoma.

An expert in follicular lymphoma highlights the therapies available for third-line relapsed/refractory treatment options.

Connie Batlevi, MD, PhD, discusses the rate of patient relapse and current treatment options and considerations for relapsed/refractory follicular lymphoma.

With the progress in diagnostic methods that has made it possible to decipher the genetic code of DLBCL within a relatively short time, and with the increasing number of drugs that are entering clinical trials, our next big challenge is to enroll patients in trials in a timely manner.